BenevolentAI
why is the right for a combination with acquisition augmented drug discovery is at an in point with the space increasingly a strategic area of focus for established companies as one of the industry leaders is uniquely positioned to bene from this paradigm shift combines a revolutionary based drug discovery platform with advanced pharmaceutical development capabilities and commercially validated platform exploits a vast set of data points to identify truly novel drug targets across therapeutic areas and with a particular focus on complex diseases with material medical need advanced laboratory capabilities help move programmes faster and generate data at scale for continuous innovation platform has a proven track record for tangible results and discoveries as an entirely novel target for the treatment of ulcerative colitis plus taken atopic dermatitis into clinic successfully as treatment for covid now approved collaborating with which has yielded novel generated target into portfolio for in bene from a highly versatile and risked business model combining multiple therapeutic areas with the ability to develop in house to out license or to collaborate with partners on new drug discovery and is led by an experienced management team with an outstanding track record in and technology supported by industry leading board members and advisors the investment opportunity represents an attractive value proposition with cant upside as evidenced by the extensive pipeline of drug candidates and the platform potential fit | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
December 2021
Slide
6 of 42
Related slides by other companies
Absci
Investor Conference
January 2023
technology validated through industry leading partnerships | Absci
Absci
Investor Presentation
March 2023
technology validated through industry leading partnerships | Absci
Absci
Investor Presentation
April 2023
partnerships technology validated through industry leading partnerships | Absci
Valo
SPAC
June 2021
aspiration is for opal to become the industry standard platform for drug discovery and development unlocking multiple business models build validate scale democratize | Valo
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io